Share:
COPENHAGEN, Denmark, May 7, 2021 – Bavarian Nordic A/S ((OMX: BAVA, OTC:BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS
® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
(0)
COPENHAGEN, Denmark, May 7, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
Danish
COPENHAGEN, Denmark, May 7, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS
® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company’s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
Operator
Good day and welcome to the Healthcare Realty Trust First Quarter Financial Results Conference Call. All participants will be in listen only mode. [Operator Instructions].
I would now like to turn the conference over to Carlos Baca, Associate Vice President Investor Relations and Corporate Responsibility. Please go ahead.
Carla Baca
Associate Vice President Investor Relations and Corporate Responsibility
Thank you for joining us today for healthcare royalties, first quarter 2021 earnings conference call. Joining me on the call today are; Todd Meredith, Bethany Mancini, Rob Hull and Kris Douglas. Reminder that except for the historical information contained within the matters discussed in this call may contain forward looking statements that involve estimates assumptions, risk and uncertainty. These risks are more specifically discussed in the form 10k filed with the SEC for the year ended December 31 2020. These forward looking statements represent the company s judg
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;